When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that sometimes cause impaired decision-making and poor ... Some Diabetes Drugs Tied to ...

“The evidence would suggest that perhaps we need to investigate this pathway and perhaps this drug in both Parkinson’s, ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...